ID   RIPK2_HUMAN             Reviewed;         540 AA.
AC   O43353; B7Z748; Q6UWF0;
DT   02-MAY-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 2.
DT   12-OCT-2022, entry version 225.
DE   RecName: Full=Receptor-interacting serine/threonine-protein kinase 2;
DE            EC=2.7.11.1;
DE   AltName: Full=CARD-containing interleukin-1 beta-converting enzyme-associated kinase;
DE            Short=CARD-containing IL-1 beta ICE-kinase;
DE   AltName: Full=RIP-like-interacting CLARP kinase;
DE   AltName: Full=Receptor-interacting protein 2;
DE            Short=RIP-2;
DE   AltName: Full=Tyrosine-protein kinase RIPK2;
DE            EC=2.7.10.2;
GN   Name=RIPK2; Synonyms=CARDIAK, RICK, RIP2;
GN   ORFNames=UNQ277/PRO314/PRO34092;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND MUTAGENESIS
RP   OF LYS-47.
RX   PubMed=9575181; DOI=10.1074/jbc.273.20.12296;
RA   Inohara N., del Peso L., Koseki T., Chen S., Nunez G.;
RT   "RICK, a novel protein kinase containing a caspase recruitment domain,
RT   interacts with CLARP and regulates CD95-mediated apoptosis.";
RL   J. Biol. Chem. 273:12296-12300(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND MUTAGENESIS
RP   OF LYS-47.
RC   TISSUE=Endothelial cell;
RX   PubMed=9642260; DOI=10.1074/jbc.273.27.16968;
RA   McCarthy J.V., Ni J., Dixit V.M.;
RT   "RIP2 is a novel NF-kappaB-activating and cell death-inducing kinase.";
RL   J. Biol. Chem. 273:16968-16975(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ACTIVE SITE, AND MUTAGENESIS OF
RP   ASP-146.
RC   TISSUE=Pancreatic adenocarcinoma;
RX   PubMed=9705938; DOI=10.1016/s0960-9822(07)00352-1;
RA   Thome M., Hofmann K., Burns K., Martinon F., Bodmer J.-L., Mattmann C.,
RA   Tschopp J.;
RT   "Identification of CARDIAK, a RIP-like kinase that associates with caspase-
RT   1.";
RL   Curr. Biol. 8:885-888(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION.
RX   PubMed=14638696; DOI=10.1074/jbc.c300460200;
RA   Ruefli-Brasse A.A., Lee W.P., Hurst S., Dixit V.M.;
RT   "Rip2 participates in Bcl10 signaling and T-cell receptor-mediated NF-
RT   kappaB activation.";
RL   J. Biol. Chem. 279:1570-1574(2004).
RN   [9]
RP   CATALYTIC ACTIVITY, AND PHOSPHORYLATION AT SER-176.
RX   PubMed=16824733; DOI=10.1016/j.cellsig.2006.05.005;
RA   Dorsch M., Wang A., Cheng H., Lu C., Bielecki A., Charron K., Clauser K.,
RA   Ren H., Polakiewicz R.D., Parsons T., Li P., Ocain T., Xu Y.;
RT   "Identification of a regulatory autophosphorylation site in the serine-
RT   threonine kinase RIP2.";
RL   Cell. Signal. 18:2223-2229(2006).
RN   [10]
RP   FUNCTION, INTERACTION WITH NOD1, AND MUTAGENESIS OF ARG-444; ARG-483 AND
RP   ARG-488.
RX   PubMed=17054981; DOI=10.1016/j.jmb.2006.09.067;
RA   Manon F., Favier A., Nunez G., Simorre J.P., Cusack S.;
RT   "Solution structure of NOD1 CARD and mutational analysis of its interaction
RT   with the CARD of downstream kinase RICK.";
RL   J. Mol. Biol. 365:160-174(2007).
RN   [11]
RP   INTERACTION WITH MAP3K4.
RX   PubMed=18775659; DOI=10.1016/j.cub.2008.07.084;
RA   Clark N.M., Marinis J.M., Cobb B.A., Abbott D.W.;
RT   "MEKK4 sequesters RIP2 to dictate NOD2 signal specificity.";
RL   Curr. Biol. 18:1402-1408(2008).
RN   [12]
RP   INTERACTION WITH IKBKG/NEMO AND MAP3K7/TAK1, FUNCTION, UBIQUITINATION AT
RP   LYS-209, AND MUTAGENESIS OF LYS-209.
RX   PubMed=18079694; DOI=10.1038/sj.emboj.7601962;
RA   Hasegawa M., Fujimoto Y., Lucas P.C., Nakano H., Fukase K., Nunez G.,
RA   Inohara N.;
RT   "A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-kappaB
RT   activation.";
RL   EMBO J. 27:373-383(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-363; SER-527 AND SER-539, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-531, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   UBIQUITINATION BY ITCH, AND INTERACTION WITH NOD2.
RX   PubMed=19592251; DOI=10.1016/j.cub.2009.06.038;
RA   Tao M., Scacheri P.C., Marinis J.M., Harhaj E.W., Matesic L.E.,
RA   Abbott D.W.;
RT   "ITCH K63-ubiquitinates the NOD2 binding protein, RIP2, to influence
RT   inflammatory signaling pathways.";
RL   Curr. Biol. 19:1255-1263(2009).
RN   [16]
RP   UBIQUITINATION BY BIRC2 AND BIRC3.
RX   PubMed=19464198; DOI=10.1016/j.immuni.2009.04.011;
RA   Bertrand M.J., Doiron K., Labbe K., Korneluk R.G., Barker P.A., Saleh M.;
RT   "Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate
RT   immunity signaling by the pattern recognition receptors NOD1 and NOD2.";
RL   Immunity 30:789-801(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-168; SER-363; SER-393;
RP   SER-527 AND SER-539, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [18]
RP   FUNCTION, PHOSPHORYLATION AT TYR-474, AND MUTAGENESIS OF TYR-474.
RX   PubMed=21123652; DOI=10.1101/gad.1964410;
RA   Tigno-Aranjuez J.T., Asara J.M., Abbott D.W.;
RT   "Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine
RT   responses.";
RL   Genes Dev. 24:2666-2677(2010).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-529, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [21]
RP   UBIQUITINATION BY BIRC2/C-IAP1 AND BIRC3/C-IAP2, AND INTERACTION WITH
RP   BIRC2/C-IAP1; BIRC3/C-IAP2 AND XIAP/BIRC4.
RX   PubMed=21931591; DOI=10.1371/journal.pone.0022356;
RA   Bertrand M.J., Lippens S., Staes A., Gilbert B., Roelandt R., De Medts J.,
RA   Gevaert K., Declercq W., Vandenabeele P.;
RT   "cIAP1/2 are direct E3 ligases conjugating diverse types of ubiquitin
RT   chains to receptor interacting proteins kinases 1 to 4 (RIP1-4).";
RL   PLoS ONE 6:E22356-E22356(2011).
RN   [22]
RP   ACETYLATION AT THR-149; SER-174; SER-178; SER-178; SER-181; SER-183;
RP   THR-189; SER-363; THR-397 AND SER-423 (MICROBIAL INFECTION).
RX   PubMed=22520462; DOI=10.1016/j.chom.2012.02.009;
RA   Meinzer U., Barreau F., Esmiol-Welterlin S., Jung C., Villard C., Leger T.,
RA   Ben-Mkaddem S., Berrebi D., Dussaillant M., Alnabhani Z., Roy M.,
RA   Bonacorsi S., Wolf-Watz H., Perroy J., Ollendorff V., Hugot J.P.;
RT   "Yersinia pseudotuberculosis effector YopJ subverts the Nod2/RICK/TAK1
RT   pathway and activates caspase-1 to induce intestinal barrier dysfunction.";
RL   Cell Host Microbe 11:337-351(2012).
RN   [23]
RP   INTERACTION WITH NLRP10.
RX   PubMed=22672233; DOI=10.1111/j.1462-5822.2012.01822.x;
RA   Lautz K., Damm A., Menning M., Wenger J., Adam A.C., Zigrino P.,
RA   Kremmer E., Kufer T.A.;
RT   "NLRP10 enhances Shigella-induced pro-inflammatory responses.";
RL   Cell. Microbiol. 14:1568-1583(2012).
RN   [24]
RP   FUNCTION, SUBCELLULAR LOCATION, IDENTIFICATION IN A COMPLEX WITH ARHGEF2
RP   AND NOD2, INTERACTION WITH ARHGEF2 AND NOD2, PHOSPHORYLATION AT TYR-381,
RP   AND MUTAGENESIS OF TYR-381.
RX   PubMed=21887730; DOI=10.1002/ibd.21851;
RA   Zhao Y., Alonso C., Ballester I., Song J.H., Chang S.Y., Guleng B.,
RA   Arihiro S., Murray P.J., Xavier R., Kobayashi K.S., Reinecker H.C.;
RT   "Control of NOD2 and Rip2-dependent innate immune activation by GEF-H1.";
RL   Inflamm. Bowel Dis. 18:603-612(2012).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-363; SER-527; SER-529 AND
RP   SER-531, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   UBIQUITINATION, AND DEUBIQUITINATION.
RX   PubMed=23806334; DOI=10.1016/j.molcel.2013.06.004;
RA   Fiil B.K., Damgaard R.B., Wagner S.A., Keusekotten K., Fritsch M.,
RA   Bekker-Jensen S., Mailand N., Choudhary C., Komander D., Gyrd-Hansen M.;
RT   "OTULIN restricts Met1-linked ubiquitination to control innate immune
RT   signaling.";
RL   Mol. Cell 50:818-830(2013).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [28]
RP   INTERACTION WITH NOD2.
RX   PubMed=27812135; DOI=10.1371/journal.pone.0165420;
RA   Thiebaut R., Esmiol S., Lecine P., Mahfouz B., Hermant A., Nicoletti C.,
RA   Parnis S., Perroy J., Borg J.P., Pascoe L., Hugot J.P., Ollendorff V.;
RT   "Characterization and Genetic Analyses of New Genes Coding for NOD2
RT   Interacting Proteins.";
RL   PLoS ONE 11:E0165420-E0165420(2016).
RN   [29]
RP   INTERACTION WITH INAVA.
RX   PubMed=28436939; DOI=10.1172/jci86282;
RA   Yan J., Hedl M., Abraham C.;
RT   "An inflammatory bowel disease-risk variant in INAVA decreases pattern
RT   recognition receptor-induced outcomes.";
RL   J. Clin. Invest. 127:2192-2205(2017).
RN   [30]
RP   FUNCTION, SUBCELLULAR LOCATION, UBIQUITINATION AT LYS-503, AND MUTAGENESIS
RP   OF LYS-503.
RX   PubMed=28656966; DOI=10.1038/ncomms15865;
RA   Bist P., Cheong W.S., Ng A., Dikshit N., Kim B.H., Pulloor N.K.,
RA   Khameneh H.J., Hedl M., Shenoy A.R., Balamuralidhar V., Malik N.B.A.,
RA   Hong M., Neutzner A., Chin K.C., Kobayashi K.S., Bertoletti A.,
RA   Mortellaro A., Abraham C., MacMicking J.D., Xavier R.J., Sukumaran B.;
RT   "E3 Ubiquitin ligase ZNRF4 negatively regulates NOD2 signalling and induces
RT   tolerance to MDP.";
RL   Nat. Commun. 8:15865-15865(2017).
RN   [31] {ECO:0007744|PDB:2N7Z, ECO:0007744|PDB:2N83}
RP   STRUCTURE BY NMR OF 434-539 IN COMPLEX WITH NGFR, FUNCTION, AND MUTAGENESIS
RP   OF GLN-437; ASP-467; LYS-471; ILE-496; GLU-500 AND ARG-528.
RX   PubMed=26646181; DOI=10.7554/elife.11692;
RA   Lin Z., Tann J.Y., Goh E.T., Kelly C., Lim K.B., Gao J.F., Ibanez C.F.;
RT   "Structural basis of death domain signaling in the p75 neurotrophin
RT   receptor.";
RL   Elife 4:e11692-e11692(2015).
RN   [32]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-259; VAL-268 AND ASN-313.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine/tyrosine kinase that plays an essential role
CC       in modulation of innate and adaptive immune responses (PubMed:9575181,
CC       PubMed:9642260, PubMed:17054981, PubMed:21123652, PubMed:21887730,
CC       PubMed:28656966). Upon stimulation by bacterial peptidoglycans, NOD1
CC       and NOD2 are activated, oligomerize and recruit RIPK2 through CARD-CARD
CC       domains (PubMed:17054981, PubMed:21123652, PubMed:28656966).
CC       Contributes to the tyrosine phosphorylation of the guanine exchange
CC       factor ARHGEF2 through Src tyrosine kinase leading to NF-kappa-B
CC       activation by NOD2 (PubMed:21123652). Once recruited, RIPK2
CC       autophosphorylates and undergoes 'Lys-63'-linked polyubiquitination by
CC       E3 ubiquitin ligases XIAP, BIRC2 and BIRC3. The polyubiquitinated
CC       protein mediates the recruitment of MAP3K7/TAK1 to IKBKG/NEMO and
CC       induces 'Lys-63'-linked polyubiquitination of IKBKG/NEMO and subsequent
CC       activation of IKBKB/IKKB (PubMed:18079694). In turn, NF-kappa-B is
CC       released from NF-kappa-B inhibitors and translocates into the nucleus
CC       where it activates the transcription of hundreds of genes involved in
CC       immune response, growth control, or protection against apoptosis
CC       (PubMed:18079694). Also plays a role during engagement of the T-cell
CC       receptor (TCR) in promoting BCL10 phosphorylation and subsequent NF-
CC       kappa-B activation (PubMed:14638696). Plays a role in the inactivation
CC       of RHOA in response to NGFR signaling (PubMed:26646181).
CC       {ECO:0000269|PubMed:14638696, ECO:0000269|PubMed:17054981,
CC       ECO:0000269|PubMed:18079694, ECO:0000269|PubMed:21123652,
CC       ECO:0000269|PubMed:21887730, ECO:0000269|PubMed:26646181,
CC       ECO:0000269|PubMed:28656966, ECO:0000269|PubMed:9575181,
CC       ECO:0000269|PubMed:9642260}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10027,
CC         ECO:0000269|PubMed:16824733};
CC   -!- SUBUNIT: Found in a signaling complex consisting of at least ARHGEF2,
CC       NOD2 and RIPK2. Interacts with ARHGEF2; the interaction mediates
CC       tyrosine phosphorylation of RIPK2 by Src kinase CSK. Binds to
CC       CFLAR/CLARP and CASP1 via their CARD domains. Binds to BIRC3/c-IAP1 and
CC       BIRC2/c-IAP2, TRAF1, TRAF2, TRAF5 and TRAF6. May be a component of both
CC       the TNFRSF1A and TNRFSF5/CD40 receptor complex. Interacts with NOD1.
CC       Interacts (via CARD domain) with NOD2 (via CARD domain)
CC       (PubMed:19592251, PubMed:21887730, PubMed:27812135). Interacts with
CC       MAP3K4; this interaction sequesters RIPK2 from the NOD2 signaling
CC       pathway. Interacts with IKBKG/NEMO. The polyubiquitinated protein
CC       interacts with MAP3K7/TAK1. Interacts with XIAP/BIRC4. Interacts with
CC       NLRP10. Interacts with CARD9. Interacts with INAVA; the interaction
CC       takes place upon PRR stimulation (PubMed:28436939). Interacts (via CARD
CC       domain) with NGFR (via death domain) (PubMed:26646181).
CC       {ECO:0000269|PubMed:17054981, ECO:0000269|PubMed:18079694,
CC       ECO:0000269|PubMed:18775659, ECO:0000269|PubMed:19592251,
CC       ECO:0000269|PubMed:21887730, ECO:0000269|PubMed:21931591,
CC       ECO:0000269|PubMed:22672233, ECO:0000269|PubMed:26646181,
CC       ECO:0000269|PubMed:27812135, ECO:0000269|PubMed:28436939}.
CC   -!- INTERACTION:
CC       O43353; Q13490: BIRC2; NbExp=3; IntAct=EBI-358522, EBI-514538;
CC       O43353; Q13489: BIRC3; NbExp=3; IntAct=EBI-358522, EBI-517709;
CC       O43353; Q9BX69: CARD6; NbExp=2; IntAct=EBI-358522, EBI-14405242;
CC       O43353; Q7Z434: MAVS; NbExp=3; IntAct=EBI-358522, EBI-995373;
CC       O43353; Q9HC29: NOD2; NbExp=3; IntAct=EBI-358522, EBI-7445625;
CC       O43353; O43353: RIPK2; NbExp=6; IntAct=EBI-358522, EBI-358522;
CC       O43353; Q12933: TRAF2; NbExp=2; IntAct=EBI-358522, EBI-355744;
CC       O43353; Q13114: TRAF3; NbExp=6; IntAct=EBI-358522, EBI-357631;
CC       O43353; P98170: XIAP; NbExp=21; IntAct=EBI-358522, EBI-517127;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:21887730}.
CC       Endoplasmic reticulum {ECO:0000269|PubMed:28656966}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O43353-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O43353-2; Sequence=VSP_013266;
CC   -!- TISSUE SPECIFICITY: Detected in heart, brain, placenta, lung,
CC       peripheral blood leukocytes, spleen, kidney, testis, prostate, pancreas
CC       and lymph node. {ECO:0000269|PubMed:9575181,
CC       ECO:0000269|PubMed:9642260}.
CC   -!- DOMAIN: Contains an N-terminal kinase domain and a C-terminal caspase
CC       activation and recruitment domain (CARD) that mediates the recruitment
CC       of CARD-containing proteins. {ECO:0000269|PubMed:26646181}.
CC   -!- PTM: Autophosphorylated. Autophosphorylation at Tyr-474 is necessary
CC       for effective NOD2 signaling. Phosphorylated. Phosphorylation at Tyr-
CC       381 by Src kinase CSK occurs in a ARHGEF2-dependent manner and is
CC       required for NOD2-dependent innate immune activation.
CC       {ECO:0000269|PubMed:16824733, ECO:0000269|PubMed:21123652,
CC       ECO:0000269|PubMed:21887730}.
CC   -!- PTM: Ubiquitinated on Lys-209; undergoes 'Lys-63'-linked
CC       polyubiquitination catalyzed by ITCH (PubMed:19592251,
CC       PubMed:18079694). Polyubiquitinated with 'Lys-48' and 'Lys-63'-linked
CC       chains by BIRC2/c-IAP1 and BIRC3/c-IAP2, leading to activation of NF-
CC       kappa-B (PubMed:19464198, PubMed:21931591). Also undergoes 'Met-1'-
CC       linked polyubiquitination; the head-to-tail linear polyubiquitination
CC       is mediated by the LUBAC complex in response to NOD2 stimulation
CC       (PubMed:23806334). Linear polyubiquitination is restricted by
CC       FAM105B/otulin, probably to limit NOD2-dependent pro-inflammatory
CC       signaling activation of NF-kappa-B (PubMed:23806334). Undergoes 'Lys-
CC       63'-linked deubiquitination by MYSM1 to attenuate NOD2-mediated
CC       inflammation and tissue damage (By similarity). Ubiquitination at Lys-
CC       503 by ZNRF4 via 'Lys-48'-linked polyubiquitination promotes RIPK2
CC       degradation by the proteasome; ubiquitination by ZNRF4 takes place
CC       during both acute and NOD2 tolerance conditions (PubMed:28656966).
CC       {ECO:0000250|UniProtKB:P58801, ECO:0000269|PubMed:18079694,
CC       ECO:0000269|PubMed:19464198, ECO:0000269|PubMed:19592251,
CC       ECO:0000269|PubMed:21931591, ECO:0000269|PubMed:23806334,
CC       ECO:0000269|PubMed:28656966}.
CC   -!- PTM: (Microbial infection) Acetylation of Ser-174, Ser-176 and Ser-178
CC       by Yersinia YopJ prevents phosphorylation and activation, thereby
CC       promoting cell death. {ECO:0000269|PubMed:22520462}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF027706; AAC34970.1; -; mRNA.
DR   EMBL; AF078530; AAC27722.1; -; mRNA.
DR   EMBL; AF064824; AAC25668.1; -; mRNA.
DR   EMBL; AY358813; AAQ89172.1; -; mRNA.
DR   EMBL; AY358814; AAQ89173.1; -; mRNA.
DR   EMBL; AK301448; BAH13484.1; -; mRNA.
DR   EMBL; AC004003; AAC24561.1; -; Genomic_DNA.
DR   EMBL; AF117829; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC004553; AAH04553.1; -; mRNA.
DR   CCDS; CCDS6247.1; -. [O43353-1]
DR   RefSeq; NP_003812.1; NM_003821.5. [O43353-1]
DR   RefSeq; XP_005251149.1; XM_005251092.3.
DR   PDB; 2N7Z; NMR; -; A=434-539.
DR   PDB; 2N83; NMR; -; B=434-539.
DR   PDB; 4C8B; X-ray; 2.75 A; A/B=8-317.
DR   PDB; 5AR2; X-ray; 2.44 A; A/B=1-310.
DR   PDB; 5AR3; X-ray; 3.23 A; A/B=1-310.
DR   PDB; 5AR4; X-ray; 2.70 A; A/B=1-310.
DR   PDB; 5AR5; X-ray; 2.66 A; A/B=1-310.
DR   PDB; 5AR7; X-ray; 2.71 A; A/B=1-310.
DR   PDB; 5AR8; X-ray; 2.79 A; A/B=1-310.
DR   PDB; 5J79; X-ray; 2.69 A; A/B=1-310.
DR   PDB; 5J7B; X-ray; 2.53 A; A/B=1-310.
DR   PDB; 5NG0; X-ray; 2.00 A; A/B=1-300.
DR   PDB; 5NG2; X-ray; 2.80 A; A/B=1-300.
DR   PDB; 5NG3; X-ray; 2.60 A; A/B/C/D=1-300.
DR   PDB; 5W5J; X-ray; 2.85 A; A/B=2-311.
DR   PDB; 5W5O; X-ray; 2.89 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P=2-311.
DR   PDB; 5YRN; EM; 4.10 A; A/B/C/D/E/F/G/H/I/J/K/L=434-540.
DR   PDB; 6ES0; X-ray; 2.38 A; A/B=3-317.
DR   PDB; 6FU5; X-ray; 3.26 A; A/B=3-317.
DR   PDB; 6GFJ; X-ray; 3.30 A; A/B/C/D=435-540.
DR   PDB; 6GGS; EM; 3.94 A; A/B/C/D/E/F/G/H/I/J=431-540.
DR   PDB; 6HMX; X-ray; 2.53 A; A/B=1-310.
DR   PDB; 6RN8; X-ray; 2.69 A; A/B=1-310.
DR   PDB; 6RNA; X-ray; 2.62 A; A/B=1-310.
DR   PDB; 6S1F; X-ray; 3.11 A; A/B/C/D=3-317.
DR   PDB; 6SZE; X-ray; 2.94 A; A/B=1-310.
DR   PDB; 6SZJ; X-ray; 2.53 A; A/B=1-310.
DR   PDB; 6UL8; X-ray; 2.68 A; A/B=5-310.
DR   PDBsum; 2N7Z; -.
DR   PDBsum; 2N83; -.
DR   PDBsum; 4C8B; -.
DR   PDBsum; 5AR2; -.
DR   PDBsum; 5AR3; -.
DR   PDBsum; 5AR4; -.
DR   PDBsum; 5AR5; -.
DR   PDBsum; 5AR7; -.
DR   PDBsum; 5AR8; -.
DR   PDBsum; 5J79; -.
DR   PDBsum; 5J7B; -.
DR   PDBsum; 5NG0; -.
DR   PDBsum; 5NG2; -.
DR   PDBsum; 5NG3; -.
DR   PDBsum; 5W5J; -.
DR   PDBsum; 5W5O; -.
DR   PDBsum; 5YRN; -.
DR   PDBsum; 6ES0; -.
DR   PDBsum; 6FU5; -.
DR   PDBsum; 6GFJ; -.
DR   PDBsum; 6GGS; -.
DR   PDBsum; 6HMX; -.
DR   PDBsum; 6RN8; -.
DR   PDBsum; 6RNA; -.
DR   PDBsum; 6S1F; -.
DR   PDBsum; 6SZE; -.
DR   PDBsum; 6SZJ; -.
DR   PDBsum; 6UL8; -.
DR   AlphaFoldDB; O43353; -.
DR   SMR; O43353; -.
DR   BioGRID; 114300; 70.
DR   DIP; DIP-27518N; -.
DR   IntAct; O43353; 27.
DR   MINT; O43353; -.
DR   STRING; 9606.ENSP00000220751; -.
DR   BindingDB; O43353; -.
DR   ChEMBL; CHEMBL5014; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; O43353; -.
DR   GuidetoPHARMACOLOGY; 2190; -.
DR   GlyGen; O43353; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O43353; -.
DR   PhosphoSitePlus; O43353; -.
DR   BioMuta; RIPK2; -.
DR   EPD; O43353; -.
DR   jPOST; O43353; -.
DR   MassIVE; O43353; -.
DR   MaxQB; O43353; -.
DR   PaxDb; O43353; -.
DR   PeptideAtlas; O43353; -.
DR   PRIDE; O43353; -.
DR   ProteomicsDB; 48908; -. [O43353-1]
DR   ProteomicsDB; 48909; -. [O43353-2]
DR   Antibodypedia; 12695; 675 antibodies from 44 providers.
DR   DNASU; 8767; -.
DR   Ensembl; ENST00000220751.5; ENSP00000220751.4; ENSG00000104312.8. [O43353-1]
DR   GeneID; 8767; -.
DR   KEGG; hsa:8767; -.
DR   MANE-Select; ENST00000220751.5; ENSP00000220751.4; NM_003821.6; NP_003812.1.
DR   UCSC; uc003yee.4; human. [O43353-1]
DR   CTD; 8767; -.
DR   DisGeNET; 8767; -.
DR   GeneCards; RIPK2; -.
DR   HGNC; HGNC:10020; RIPK2.
DR   HPA; ENSG00000104312; Low tissue specificity.
DR   MIM; 603455; gene.
DR   neXtProt; NX_O43353; -.
DR   OpenTargets; ENSG00000104312; -.
DR   PharmGKB; PA34395; -.
DR   VEuPathDB; HostDB:ENSG00000104312; -.
DR   eggNOG; KOG0192; Eukaryota.
DR   GeneTree; ENSGT00940000156113; -.
DR   HOGENOM; CLU_000288_7_35_1; -.
DR   InParanoid; O43353; -.
DR   OMA; CPVNHSW; -.
DR   PhylomeDB; O43353; -.
DR   TreeFam; TF106506; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   BRENDA; 2.7.11.30; 2681.
DR   PathwayCommons; O43353; -.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-209543; p75NTR recruits signalling complexes.
DR   Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-HSA-450302; activated TAK1 mediates p38 MAPK activation.
DR   Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; R-HSA-5689896; Ovarian tumor domain proteases.
DR   Reactome; R-HSA-9020702; Interleukin-1 signaling.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   SignaLink; O43353; -.
DR   SIGNOR; O43353; -.
DR   BioGRID-ORCS; 8767; 10 hits in 1119 CRISPR screens.
DR   ChiTaRS; RIPK2; human.
DR   GeneWiki; RIPK2; -.
DR   GenomeRNAi; 8767; -.
DR   Pharos; O43353; Tchem.
DR   PRO; PR:O43353; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; O43353; protein.
DR   Bgee; ENSG00000104312; Expressed in cartilage tissue and 173 other tissues.
DR   ExpressionAtlas; O43353; baseline and differential.
DR   Genevisible; O43353; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0031982; C:vesicle; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0050700; F:CARD domain binding; IDA:MGI.
DR   GO; GO:0089720; F:caspase binding; IPI:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004706; F:JUN kinase kinase kinase activity; IBA:GO_Central.
DR   GO; GO:0030274; F:LIM domain binding; IPI:UniProtKB.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:UniProtKB.
DR   GO; GO:0097202; P:activation of cysteine-type endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0002250; P:adaptive immune response; ISS:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:ProtInc.
DR   GO; GO:0035739; P:CD4-positive, alpha-beta T cell proliferation; IEA:Ensembl.
DR   GO; GO:0071223; P:cellular response to lipoteichoic acid; IEA:Ensembl.
DR   GO; GO:0071225; P:cellular response to muramyl dipeptide; IDA:UniProtKB.
DR   GO; GO:0071224; P:cellular response to peptidoglycan; IEA:Ensembl.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; ISS:UniProtKB.
DR   GO; GO:0033080; P:immature T cell proliferation in thymus; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0045087; P:innate immune response; IDA:UniProtKB.
DR   GO; GO:0007254; P:JNK cascade; IEA:Ensembl.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0070427; P:nucleotide-binding oligomerization domain containing 1 signaling pathway; IEA:Ensembl.
DR   GO; GO:0070431; P:nucleotide-binding oligomerization domain containing 2 signaling pathway; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:2000563; P:positive regulation of CD4-positive, alpha-beta T cell proliferation; IEA:Ensembl.
DR   GO; GO:0010942; P:positive regulation of cell death; IDA:UniProtKB.
DR   GO; GO:0032722; P:positive regulation of chemokine production; IEA:Ensembl.
DR   GO; GO:0001961; P:positive regulation of cytokine-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IDA:MGI.
DR   GO; GO:0033092; P:positive regulation of immature T cell proliferation in thymus; IEA:Ensembl.
DR   GO; GO:0032727; P:positive regulation of interferon-alpha production; NAS:BHF-UCL.
DR   GO; GO:0032728; P:positive regulation of interferon-beta production; NAS:BHF-UCL.
DR   GO; GO:0032729; P:positive regulation of interferon-gamma production; IEA:Ensembl.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; IDA:UniProtKB.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; NAS:BHF-UCL.
DR   GO; GO:0032743; P:positive regulation of interleukin-2 production; IEA:Ensembl.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IEA:Ensembl.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IEA:Ensembl.
DR   GO; GO:0060907; P:positive regulation of macrophage cytokine production; IEA:Ensembl.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; IDA:UniProtKB.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0032092; P:positive regulation of protein binding; IMP:UniProtKB.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IMP:UniProtKB.
DR   GO; GO:0045627; P:positive regulation of T-helper 1 cell differentiation; IEA:Ensembl.
DR   GO; GO:0002827; P:positive regulation of T-helper 1 type immune response; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; NAS:BHF-UCL.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:1904417; P:positive regulation of xenophagy; IEA:Ensembl.
DR   GO; GO:0043330; P:response to exogenous dsRNA; IEA:Ensembl.
DR   GO; GO:0070555; P:response to interleukin-1; IEA:Ensembl.
DR   GO; GO:0070671; P:response to interleukin-12; IEA:Ensembl.
DR   GO; GO:0070673; P:response to interleukin-18; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0034134; P:toll-like receptor 2 signaling pathway; IDA:MGI.
DR   GO; GO:0034142; P:toll-like receptor 4 signaling pathway; IEA:Ensembl.
DR   GO; GO:0098792; P:xenophagy; IEA:Ensembl.
DR   CDD; cd08786; CARD_RIP2_CARD3; 1.
DR   Gene3D; 1.10.533.10; -; 1.
DR   InterPro; IPR001315; CARD.
DR   InterPro; IPR042149; CARD_RIP2.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017322; Rcpt-int_Ser/Thr_kinase-2.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00619; CARD; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PIRSF; PIRSF037921; STPK_RIP2; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF47986; SSF47986; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50209; CARD; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Adaptive immunity; Alternative splicing;
KW   Apoptosis; ATP-binding; Cytoplasm; Endoplasmic reticulum; Immunity;
KW   Innate immunity; Isopeptide bond; Kinase; Nucleotide-binding;
KW   Phosphoprotein; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase; Ubl conjugation.
FT   CHAIN           1..540
FT                   /note="Receptor-interacting serine/threonine-protein kinase
FT                   2"
FT                   /id="PRO_0000086608"
FT   DOMAIN          18..294
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          432..524
FT                   /note="CARD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00046"
FT   REGION          338..369
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        338..368
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        146
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000269|PubMed:9705938"
FT   BINDING         24..32
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         47
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         149
FT                   /note="(Microbial infection) O-acetylthreonine; by Yersinia
FT                   YopJ"
FT                   /evidence="ECO:0000269|PubMed:22520462"
FT   MOD_RES         168
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         174
FT                   /note="(Microbial infection) O-acetylserine; by Yersinia
FT                   YopJ"
FT                   /evidence="ECO:0000269|PubMed:22520462"
FT   MOD_RES         176
FT                   /note="(Microbial infection) O-acetylserine; by Yersinia
FT                   YopJ; alternate"
FT                   /evidence="ECO:0000269|PubMed:22520462"
FT   MOD_RES         176
FT                   /note="Phosphoserine; by autocatalysis; alternate"
FT                   /evidence="ECO:0000269|PubMed:16824733"
FT   MOD_RES         178
FT                   /note="(Microbial infection) O-acetylserine; by Yersinia
FT                   YopJ"
FT                   /evidence="ECO:0000269|PubMed:22520462"
FT   MOD_RES         181
FT                   /note="(Microbial infection) O-acetylserine; by Yersinia
FT                   YopJ"
FT                   /evidence="ECO:0000269|PubMed:22520462"
FT   MOD_RES         183
FT                   /note="(Microbial infection) O-acetylserine; by Yersinia
FT                   YopJ"
FT                   /evidence="ECO:0000269|PubMed:22520462"
FT   MOD_RES         189
FT                   /note="(Microbial infection) O-acetylthreonine; by Yersinia
FT                   YopJ"
FT                   /evidence="ECO:0000269|PubMed:22520462"
FT   MOD_RES         363
FT                   /note="(Microbial infection) O-acetylserine; by Yersinia
FT                   YopJ"
FT                   /evidence="ECO:0000269|PubMed:22520462"
FT   MOD_RES         363
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   MOD_RES         381
FT                   /note="Phosphotyrosine; by CSK"
FT                   /evidence="ECO:0000269|PubMed:21887730"
FT   MOD_RES         393
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         397
FT                   /note="(Microbial infection) O-acetylthreonine; by Yersinia
FT                   YopJ"
FT                   /evidence="ECO:0000269|PubMed:22520462"
FT   MOD_RES         423
FT                   /note="(Microbial infection) O-acetylserine; by Yersinia
FT                   YopJ"
FT                   /evidence="ECO:0000269|PubMed:22520462"
FT   MOD_RES         474
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:21123652"
FT   MOD_RES         527
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:23186163"
FT   MOD_RES         529
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         531
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         539
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   CROSSLNK        209
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:18079694"
FT   CROSSLNK        503
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:28656966"
FT   VAR_SEQ         1..137
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:12975309,
FT                   ECO:0000303|PubMed:14702039"
FT                   /id="VSP_013266"
FT   VARIANT         259
FT                   /note="I -> T (in dbSNP:rs2230801)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041045"
FT   VARIANT         268
FT                   /note="L -> V (in dbSNP:rs35004667)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041046"
FT   VARIANT         313
FT                   /note="K -> N (in dbSNP:rs35395048)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041047"
FT   MUTAGEN         47
FT                   /note="K->A: Abolishes kinase activity."
FT                   /evidence="ECO:0000269|PubMed:9575181,
FT                   ECO:0000269|PubMed:9642260"
FT   MUTAGEN         47
FT                   /note="K->M: Reduces FAS-mediated apoptosis."
FT                   /evidence="ECO:0000269|PubMed:9575181,
FT                   ECO:0000269|PubMed:9642260"
FT   MUTAGEN         146
FT                   /note="D->N: Abolishes kinase activity."
FT                   /evidence="ECO:0000269|PubMed:9705938"
FT   MUTAGEN         209
FT                   /note="K->R: Complete loss of polyubiquitination."
FT                   /evidence="ECO:0000269|PubMed:18079694"
FT   MUTAGEN         381
FT                   /note="Y->A: Prevents phosphorylation. Reduces serine and
FT                   threonine phosphorylation of ARHGEF2."
FT                   /evidence="ECO:0000269|PubMed:21887730"
FT   MUTAGEN         437
FT                   /note="Q->E: Decreased interaction with NGFR."
FT                   /evidence="ECO:0000269|PubMed:26646181"
FT   MUTAGEN         444
FT                   /note="R->E: Abolishes interaction with NOD1."
FT                   /evidence="ECO:0000269|PubMed:17054981"
FT   MUTAGEN         467
FT                   /note="D->R: Decreased interaction with NGFR."
FT                   /evidence="ECO:0000269|PubMed:26646181"
FT   MUTAGEN         471
FT                   /note="K->E: Decreased interaction with NGFR."
FT                   /evidence="ECO:0000269|PubMed:26646181"
FT   MUTAGEN         474
FT                   /note="Y->F: Decreases interaction with NOD2."
FT                   /evidence="ECO:0000269|PubMed:21123652"
FT   MUTAGEN         483
FT                   /note="R->E: Abolishes interaction with NOD1."
FT                   /evidence="ECO:0000269|PubMed:17054981"
FT   MUTAGEN         488
FT                   /note="R->E: Abolishes interaction with NOD1."
FT                   /evidence="ECO:0000269|PubMed:17054981"
FT   MUTAGEN         496
FT                   /note="I->A: Decreased interaction with NGFR."
FT                   /evidence="ECO:0000269|PubMed:26646181"
FT   MUTAGEN         500
FT                   /note="E->R: Decreased interaction with NGFR."
FT                   /evidence="ECO:0000269|PubMed:26646181"
FT   MUTAGEN         503
FT                   /note="K->R: Abolished ubiquitination by ZNRF4."
FT                   /evidence="ECO:0000269|PubMed:28656966"
FT   MUTAGEN         528
FT                   /note="R->E: Decreased interaction with NGFR."
FT                   /evidence="ECO:0000269|PubMed:26646181"
FT   CONFLICT        271
FT                   /note="S -> G (in Ref. 5; BAH13484)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        514
FT                   /note="Q -> R (in Ref. 5; BAH13484)"
FT                   /evidence="ECO:0000305"
FT   STRAND          7..9
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   HELIX           15..17
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   STRAND          18..26
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   STRAND          31..37
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   TURN            38..40
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   STRAND          43..48
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   STRAND          51..53
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   HELIX           57..72
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   STRAND          81..87
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   STRAND          90..96
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   HELIX           103..108
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   TURN            110..112
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   HELIX           118..136
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   STRAND          138..140
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   HELIX           149..151
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   STRAND          152..154
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   STRAND          160..162
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   HELIX           168..176
FT                   /evidence="ECO:0007829|PDB:5NG3"
FT   TURN            189..192
FT                   /evidence="ECO:0007829|PDB:6ES0"
FT   HELIX           195..197
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   HELIX           202..205
FT                   /evidence="ECO:0007829|PDB:6ES0"
FT   HELIX           210..224
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   TURN            228..231
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   HELIX           235..243
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   TURN            252..254
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   HELIX           262..272
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   HELIX           277..279
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   HELIX           283..295
FT                   /evidence="ECO:0007829|PDB:5NG0"
FT   HELIX           300..312
FT                   /evidence="ECO:0007829|PDB:6ES0"
FT   TURN            313..315
FT                   /evidence="ECO:0007829|PDB:6ES0"
FT   HELIX           435..442
FT                   /evidence="ECO:0007829|PDB:6GFJ"
FT   HELIX           444..450
FT                   /evidence="ECO:0007829|PDB:6GFJ"
FT   HELIX           453..465
FT                   /evidence="ECO:0007829|PDB:6GFJ"
FT   HELIX           471..478
FT                   /evidence="ECO:0007829|PDB:6GFJ"
FT   STRAND          480..482
FT                   /evidence="ECO:0007829|PDB:6GFJ"
FT   HELIX           483..497
FT                   /evidence="ECO:0007829|PDB:6GFJ"
FT   HELIX           499..511
FT                   /evidence="ECO:0007829|PDB:6GFJ"
FT   STRAND          526..528
FT                   /evidence="ECO:0007829|PDB:2N7Z"
FT   TURN            530..532
FT                   /evidence="ECO:0007829|PDB:2N83"
SQ   SEQUENCE   540 AA;  61195 MW;  575A692239505792 CRC64;
     MNGEAICSAL PTIPYHKLAD LRYLSRGASG TVSSARHADW RVQVAVKHLH IHTPLLDSER
     KDVLREAEIL HKARFSYILP ILGICNEPEF LGIVTEYMPN GSLNELLHRK TEYPDVAWPL
     RFRILHEIAL GVNYLHNMTP PLLHHDLKTQ NILLDNEFHV KIADFGLSKW RMMSLSQSRS
     SKSAPEGGTI IYMPPENYEP GQKSRASIKH DIYSYAVITW EVLSRKQPFE DVTNPLQIMY
     SVSQGHRPVI NEESLPYDIP HRARMISLIE SGWAQNPDER PSFLKCLIEL EPVLRTFEEI
     TFLEAVIQLK KTKLQSVSSA IHLCDKKKME LSLNIPVNHG PQEESCGSSQ LHENSGSPET
     SRSLPAPQDN DFLSRKAQDC YFMKLHHCPG NHSWDSTISG SQRAAFCDHK TTPCSSAIIN
     PLSTAGNSER LQPGIAQQWI QSKREDIVNQ MTEACLNQSL DALLSRDLIM KEDYELVSTK
     PTRTSKVRQL LDTTDIQGEE FAKVIVQKLK DNKQMGLQPY PEILVVSRSP SLNLLQNKSM
//
